MARKET

SLDB

SLDB

Solid Bioscience
NASDAQ
8.67
+0.13
+1.51%
Opening 09:50 04/26 EDT
OPEN
8.52
PREV CLOSE
8.54
HIGH
8.81
LOW
8.41
VOLUME
3.85K
TURNOVER
0
52 WEEK HIGH
15.05
52 WEEK LOW
1.810
MARKET CAP
327.32M
P/E (TTM)
-1.7953
1D
5D
1M
3M
1Y
5Y
Edgewise gets EU orphan drug status for muscular dystrophy drug
Edgewise gets EU orphan drug status for muscular dystrophy drug. Edgewise Therapeutics has received orphan drug designation from EU regulators for its drug candidate sevasemten. The drug candidate is in the treatment of Becker muscular dy Strophy and Duchenne muscular dystrophy.
Seeking Alpha · 2d ago
Weekly Report: what happened at SLDB last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at SLDB last week (0408-0412)?
Weekly Report · 04/15 09:09
Private equity firms invested in Solid Biosciences Inc. (NASDAQ:SLDB) copped the brunt of last week's US$64m market cap decline
Solid Biosciences Inc. (NASDAQ:SLDB) has a total of 50% ownership of the company. Private equity firms own 37% of Solid B biosciences. The company is owned by 5 shareholders, with a majority of the stock in private equity firms. The top 5 shareholders of the firm are believed to have a significant influence over the business. We look at the company's ownership of shares to see how the company operates.
Simply Wall St · 04/11 11:59
Buy Solid Biosciences: Unpacking Its Main Value Driver
Seeking Alpha · 04/10 23:32
Weekly Report: what happened at SLDB last week (0401-0405)?
Weekly Report · 04/08 09:10
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Inc. Is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The company announced the grant of inducement awards to two newly hired employees. The grants were made pursuant to the Company's 2024 Inducement Stock Incentive Plan.
Barchart · 04/03 15:05
Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug
NASDAQ · 04/02 14:35
More
About SLDB
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. The Company also has two cardiac pipeline gene transfer programs, SGT-601 for TNNT2 DCM and SGT-701 for RBM20 DCM, that are both in early preclinical development. It also has a neuromuscular gene transfer program for the treatment of Friedreich's ataxia. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including novel capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.

Webull offers Solid Biosciences Inc stock information, including NASDAQ: SLDB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLDB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLDB stock methods without spending real money on the virtual paper trading platform.